{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:54:05Z","timestamp":1762005245100,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["10\/135\/02"],"award-info":[{"award-number":["10\/135\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Parkinson\u2019s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and\/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD\u00ae). NHS SLT is tailored to the individuals\u2019 needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD\u00ae comprises 16 sessions of individual treatment with home-based practice over 4\u2009weeks. The evidence-base for their effectiveness is inconclusive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2\u2009years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD\u00ae via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD\u00ae) weeks of randomisation.<\/jats:p>\n                <jats:p>Primary outcome: Voice Handicap Index (VHI) total score at 3\u2009months. Secondary outcomes include: VHI subscales, Parkinson\u2019s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5\u2009L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12\u2009months after randomisation.<\/jats:p>\n                <jats:p>The trial started in December 2015 and will run for 77\u2009months. Recruitment will take place in approximately 42 sites around the UK.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD\u00ae provide greater benefit and determine the cost-effectiveness of both interventions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>International Standard Randomised Controlled Trials Number (ISRCTN) Registry, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN12421382\">ID: 12421382<\/jats:ext-link>. Registered on 18 April 2016.\u00a0<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-020-04354-7","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T09:02:48Z","timestamp":1590570168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson\u2019s disease: a study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"21","author":[{"name":"on behalf of the PD COMM Collaborative Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Sackley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-9834","authenticated-orcid":false,"given":"C.","family":"Rick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Au","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Beaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jowett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Masterson-Algar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nicoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. E.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"issue":"11","key":"4354_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"Collaborators GBDPsD","year":"2018","unstructured":"Collaborators GBDPsD. Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939\u201353.","journal-title":"Lancet Neurol"},{"issue":"9996","key":"4354_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"key":"4354_CR3","first-page":"S528","volume-title":"Prevalence of speech impairments in Parkinson\u2019s disease: a systematic review","author":"JG Kalf","year":"2009","unstructured":"Kalf JG, de Swart BJ, Bloem BR, Munneke M. Prevalence of speech impairments in Parkinson\u2019s disease: a systematic review; 2009. p. S528\u2013S9."},{"issue":"11","key":"4354_CR4","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/jnnp.2006.110171","volume":"78","author":"N Miller","year":"2007","unstructured":"Miller N, Allcock L, Jones D, Noble E, Hildreth AJ, Burn DJ. Prevalence and pattern of perceived intelligibility changes in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2007;78(11):1188\u201390.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"4354_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000266286","volume":"46","author":"L Hartelius","year":"1994","unstructured":"Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson\u2019s disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994;46(1):9\u201317.","journal-title":"Folia Phoniatr Logop"},{"issue":"3","key":"4354_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/ageing\/afj053","volume":"35","author":"N Miller","year":"2006","unstructured":"Miller N, Noble E, Jones D, Burn D. Life with communication changes in Parkinson\u2019s disease. Age Ageing. 2006;35(3):235\u20139.","journal-title":"Age Ageing"},{"issue":"2","key":"4354_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bandl.2005.08.010","volume":"97","author":"MD Pell","year":"2006","unstructured":"Pell MD, Cheang HS, Leonard CL. The impact of Parkinson\u2019s disease on vocal-prosodic communication from the perspective of listeners. Brain Lang. 2006;97(2):123\u201334.","journal-title":"Brain Lang"},{"issue":"2S","key":"4354_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1044\/2017_AJSLP-16-0087","volume":"26","author":"K Yorkston","year":"2017","unstructured":"Yorkston K, Baylor C, Britton D. Speech versus speaking: the experiences of people with Parkinson\u2019s disease and implications for intervention. Am J Speech Lang Pathol. 2017;26(2S):561\u20138.","journal-title":"Am J Speech Lang Pathol"},{"key":"4354_CR9","unstructured":"Heberlein I, Vieregge P. The influence of speech disturbances on quality of life and coping strategies on Parkinson\u2019s disease patients. Forum Logopadie. 2005:19(3)26\u201331."},{"issue":"4","key":"4354_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/practneurol-2017-001635","volume":"17","author":"N Miller","year":"2017","unstructured":"Miller N. Communication changes in Parkinson\u2019s disease. Pract Neurol. 2017;17(4):266\u201374.","journal-title":"Pract Neurol"},{"issue":"1","key":"4354_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/1531-8257(200101)16:1<79::AID-MDS1013>3.0.CO;2-H","volume":"16","author":"LO Ramig","year":"2001","unstructured":"Ramig LO, Sapir S, Fox C, Countryman S. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson\u2019s disease: a comparison with untreated patients and normal age-matched controls. Mov Disord. 2001;16(1):79\u201383.","journal-title":"Mov Disord"},{"issue":"2","key":"4354_CR12","first-page":"189","volume":"46","author":"N Miller","year":"2011","unstructured":"Miller N, Deane KH, Jones D, Noble E, Gibb C. National survey of speech and language therapy provision for people with Parkinson\u2019 disease in the United Kingdom: therapists\u2019 practices. Int J Lang Commun Disord. 2011;46(2):189\u2013201.","journal-title":"Int J Lang Commun Disord"},{"key":"4354_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40814-017-0222-z","volume":"4","author":"CM Sackley","year":"2018","unstructured":"Sackley CM, Smith CH, Rick CE, Brady MC, Ives N, Patel S, et al. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson\u2019s disease: a pilot randomised controlled trial (PD COMM pilot). Pilot Feasibility Stud. 2018;4:30.","journal-title":"Pilot Feasibility Stud"},{"issue":"4","key":"4354_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/jnnp.71.4.493","volume":"71","author":"LO Ramig","year":"2001","unstructured":"Ramig LO, Sapir S, Countryman S, Pawlas AA, O\u2019Brien C, Hoehn M, et al. Intensive voice treatment (LSVT) for patients with Parkinson\u2019s disease: a 2 year follow up. J Neurol Neurosurg Psychiatry. 2001;71(4):493\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4354_CR15","volume":"8","author":"CP Herd","year":"2012","unstructured":"Herd CP, Tomlinson CL, Deane KH, Brady MC, Smith CH, Sackley CM, et al. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2012;8:CD002812.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4354_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/13682829009011973","volume":"25","author":"JA Johnson","year":"1990","unstructured":"Johnson JA, Pring TR. Speech therapy and Parkinson\u2019s disease: a review and further data. Br J Disord Commun. 1990;25(2):183\u201394.","journal-title":"Br J Disord Commun"},{"issue":"3","key":"4354_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/13682828409029837","volume":"19","author":"SJ Robertson","year":"1984","unstructured":"Robertson SJ, Thomson F. Speech therapy in Parkinson\u2019s disease: a study of the efficacy and long term effects of intensive treatment. Br J Disord Commun. 1984;19(3):213\u201324.","journal-title":"Br J Disord Commun."},{"key":"4354_CR18","volume":"8","author":"CP Herd","year":"2012","unstructured":"Herd CP, Tomlinson CL, Deane KH, Brady MC, Smith CH, Sackley CM, et al. Comparison of speech and language therapy techniques for speech problems in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2012;8:CD002814.","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"4354_CR19","first-page":"S105","volume":"22","author":"A Halpern","year":"2007","unstructured":"Halpern A, Spielman J, Ramig L, Cable J, Panzer I, Sharpley A. The effects of loudness and noise on speech intelligibility in Parkinson's disease. Mov Disord. 2007;22(16):S105.","journal-title":"Mov Disord"},{"issue":"11","key":"4354_CR20","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/mds.27460","volume":"33","author":"L Ramig","year":"2018","unstructured":"Ramig L, Halpern A, Spielman J, Fox C, Freeman K. Speech treatment in Parkinson\u2019s disease: randomized controlled trial (RCT). Mov Disord. 2018;33(11):1777\u201391.","journal-title":"Mov Disord"},{"issue":"3","key":"4354_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"4354_CR22","doi-asserted-by":"publisher","first-page":"g1687","DOI":"10.1136\/bmj.g1687","volume":"348","author":"TC Hoffmann","year":"2014","unstructured":"Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: Template for Intervention Description and Replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.","journal-title":"BMJ"},{"issue":"6","key":"4354_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745\u201352.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"4354_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342.","journal-title":"Neurology"},{"key":"4354_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1044\/1058-0360.0603.66","volume":"6","author":"BH Jacobson","year":"1997","unstructured":"Jacobson BH, Johnson A, Grywalski C, et al. The Voice Handicap Index (VHI): development and validation. Am J Speech Lang Pathol. 1997;6:66\u201370.","journal-title":"Am J Speech Lang Pathol"},{"issue":"2","key":"4354_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/jnnp.46.2.140","volume":"46","author":"S Scott","year":"1983","unstructured":"Scott S, Caird FI. Speech therapy for Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1983;46(2):140\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"4354_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/jnnp.47.3.302","volume":"47","author":"S Scott","year":"1984","unstructured":"Scott S, Caird FI. The response of the apparent receptive speech disorder of Parkinson\u2019s disease to speech therapy. J Neurol Neurosurg Psychiatry. 1984;47(3):302\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6299","key":"4354_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/bmj.283.6299.1088","volume":"283","author":"S Scott","year":"1981","unstructured":"Scott S, Caird FI. Speech therapy for patients with Parkinson\u2019s disease. BMJ (Clin Res Ed). 1981;283(6299):1088.","journal-title":"BMJ (Clin Res Ed)"},{"issue":"8","key":"4354_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/jnnp.46.8.789","volume":"46","author":"AE Lang","year":"1983","unstructured":"Lang AE, Fishbein V. The \u2018pacing board\u2019 in selected speech disorders of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1983;46(8):789.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4354_CR30","unstructured":"Healey V. A comparison of the efficacy of two methods of rate control in the speech of people with Parkinson\u2019s disease. Parkinson\u2019s News: A Quarterly Bulletin for Health and Social Care Professionals; 2006. p. 6\u20137."},{"issue":"3","key":"4354_CR31","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1044\/1092-4388(2008\/040)","volume":"51","author":"KC Hustad","year":"2008","unstructured":"Hustad KC. The relationship between listener comprehension and intelligibility scores for speakers with dysarthria. J Speech Lang Hear Res. 2008;51(3):562\u201373.","journal-title":"J Speech Lang Hear Res"},{"issue":"2","key":"4354_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/13682829209012034","volume":"27","author":"SG Adams","year":"1992","unstructured":"Adams SG, Lang AE. Can the Lombard effect be used to improve low voice intensity in Parkinson\u2019s disease? Eur J Disord Commun. 1992;27(2):121\u20137.","journal-title":"Eur J Disord Commun"},{"issue":"1","key":"4354_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0021-9924(99)00025-8","volume":"33","author":"GM Schulz","year":"2000","unstructured":"Schulz GM, Grant MK. Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson\u2019s disease: a review of the literature. J Commun Disord. 2000;33(1):59\u201388.","journal-title":"J Commun Disord"},{"key":"4354_CR34","first-page":"41","volume":"10","author":"BWC Rousseau","year":"2002","unstructured":"Rousseau BWC. Susceptibility of speakers with Parkinson disease to delayed feedback. J Med Speech Lang Pathol. 2002;10:41\u20139.","journal-title":"J Med Speech Lang Pathol"},{"issue":"3","key":"4354_CR35","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1212\/01.WNL.0000044480.95458.56","volume":"60","author":"BJ de Swart","year":"2003","unstructured":"de Swart BJ, Willemse SC, Maassen BA, Horstink MW. Improvement of voicing in patients with Parkinson\u2019s disease by speech therapy. Neurology. 2003;60(3):498\u2013500.","journal-title":"Neurology"},{"issue":"6","key":"4354_CR36","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1044\/jshr.3806.1232","volume":"38","author":"LO Ramig","year":"1995","unstructured":"Ramig LO, Countryman S, Thompson LL, Horii Y. Comparison of two forms of intensive speech treatment for Parkinson disease. J Speech Hear Res. 1995;38(6):1232\u201351.","journal-title":"J Speech Hear Res"},{"issue":"2","key":"4354_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1044\/1058-0360(2007\/014)","volume":"16","author":"J Spielman","year":"2007","unstructured":"Spielman J, Ramig LO, Mahler L, Halpern A, Gavin WJ. Effects of an extended version of the Lee Silverman voice treatment on voice and speech in Parkinson\u2019s disease. Am J Speech Lang Pathol. 2007;16(2):95\u2013107.","journal-title":"Am J Speech Lang Pathol"},{"issue":"3","key":"4354_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1590\/2317-1782\/20162015103","volume":"28","author":"LL Krohling","year":"2016","unstructured":"Krohling LL, Paula KM, Behlau M. ROC curve of the Pediatric Voice Related Quality-of-Life Survey (P-VRQOL). Codas. 2016;28(3):311\u20133.","journal-title":"Codas"},{"issue":"5","key":"4354_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing. 1997;26(5):353\u20137.","journal-title":"Age Ageing"},{"issue":"1","key":"4354_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000111799","volume":"60","author":"L Hartelius","year":"2008","unstructured":"Hartelius L, Elmberg M, Holm R, Lovberg AS, Nikolaidis S. Living with dysarthria: evaluation of a self-report questionnaire. Folia Phoniatr Logop. 2008;60(1):11\u20139.","journal-title":"Folia Phoniatr Logop"},{"issue":"10","key":"4354_CR41","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"Suppl 3","key":"4354_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1258\/jhsrp.2008.008024","volume":"13","author":"J Coast","year":"2008","unstructured":"Coast J, Flynn T, Sutton E, Al-Janabi H, Vosper J, Lavender S, et al. Investigating Choice Experiments for Preferences of Older People (ICEPOP): evaluative spaces in health economics. J Health Serv Res Policy. 2008;13(Suppl 3):31\u20137.","journal-title":"J Health Serv Res Policy"},{"issue":"5","key":"4354_CR43","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.parkreldis.2012.01.007","volume":"18","author":"C Jenkinson","year":"2012","unstructured":"Jenkinson C, Dummett S, Kelly L, Peters M, Dawson J, Morley D, et al. The development and validation of a quality of life measure for the carers of people with Parkinson\u2019s disease (the PDQ-Carer). Parkinsonism Relat Disord. 2012;18(5):483\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 3","key":"4354_CR44","doi-asserted-by":"publisher","first-page":"iii35","DOI":"10.1093\/ageing\/afs148","volume":"41","author":"HM Hodkinson","year":"2012","unstructured":"Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. 1972. Age Ageing. 2012;41(Suppl 3):iii35\u201340.","journal-title":"Age Ageing"},{"issue":"1","key":"4354_CR45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s13063-017-2130-1","volume":"18","author":"P Masterson-Algar","year":"2017","unstructured":"Masterson-Algar P, Burton CR, Brady MC, Nicoll A, Clarke CE, Rick C, et al. The PD COMM trial: a protocol for the process evaluation of a randomised trial assessing the effectiveness of two types of SLT for people with Parkinson\u2019s disease. Trials. 2017;18(1):397.","journal-title":"Trials"},{"key":"4354_CR46","volume-title":"Unit Costs of Health and Social Care 2017: Personal Social Services Research Unit, University of Kent","author":"L Curtis","year":"2018","unstructured":"Curtis L, Burns A. Unit Costs of Health and Social Care 2017: Personal Social Services Research Unit, University of Kent, vol. 2018; 2018."},{"key":"4354_CR47","unstructured":"2017\/2018 DoHNRC. London. 2018. https:\/\/improvement.nhs.uk\/resources\/reference-costs. Accessed 20 May 2019."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04354-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-020-04354-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04354-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T23:46:44Z","timestamp":1622072804000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04354-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4354"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04354-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial received ethical approval from the West Midlands NHS Research Ethics Committee (15\/WM\/0443) prior to all trial activity in NHS sites. The ethical approval covers all participating centres. All participants in the trial will provide informed consent prior to any trial procedure.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable \u2013 no individual\u2019s data is included.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"436"}}